HuCD33 BsAb - Y-mAbs Therapeutics
Alternative Names: huCD33-Bispecific antibody - Y-mAbs Therapeutics; huCD33-BsAb (CD33xCD3); huCD33-BsAb - Y-mAbs TherapeuticsLatest Information Update: 09 Jun 2023
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; CD33 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
- No development reported Haematological malignancies
Most Recent Events
- 25 May 2023 Y-mAbs Therapeutics terminates a phase I trial in Acute myeloid leukemia (In children, In adolescents, In adults, Second-line therapy or greater) in USA (SC), due to business priorities) (NCT05077423)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 18 May 2022 Phase-I clinical trials in Acute myeloid leukaemia (In adults, In children, In adolescents, Second-line therapy or greater) in USA (SC) (NCT05077423)